HYBRID EVENT: You can participate in person at London or Virtually from your home or work.
Paediatric Intermediate Uveitis is a complex and potentially sight-threatening inflammatory condition affecting the uvea, the middle layer of the eye, specifically prevalent in children and adolescents. This disorder manifests as inflammation primarily in the vitreous, the gel-like substance that fills the eye, as well as the adjacent tissues. Characterized by insidious onset and a chronic course, Paediatric Intermediate Uveitis often presents with nonspecific symptoms such as blurred vision, floaters, eye redness, and pain. The exact etiology remains elusive, but it is generally considered an immune-mediated response, possibly triggered by an underlying systemic condition or genetic predisposition. The diagnosis involves a comprehensive ophthalmic examination, imaging studies like optical coherence tomography (OCT), and laboratory investigations to rule out associated systemic diseases. Unlike adult intermediate uveitis, which is often idiopathic, Paediatric Intermediate Uveitis is frequently associated with systemic disorders such as juvenile idiopathic arthritis (JIA) and sarcoidosis. Management typically necessitates a multidisciplinary approach involving Paediatric rheumatologists and ophthalmologists. Topical and systemic corticosteroids are the mainstay of treatment to quell inflammation, but immunomodulatory agents such as methotrexate and biologics may be employed for cases refractory to conventional therapy or to minimize steroid-related side effects. Long-term follow-up is crucial to monitor for potential complications, including cataracts, glaucoma, and vision loss, underscoring the importance of early detection and a vigilant, collaborative healthcare strategy to optimize outcomes for Paediatric patients grappling with Intermediate Uveitis.
